Eventide Asset Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Eventide Asset Management’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-336,223	Closed	-$2.84M	–	149
2022 Q2	$2.84M	Hold	336,223	–	–	0.06%	129
2022 Q1	$4.58M	Hold	336,223	–	–	0.07%	124
2021 Q4	$6.61M	Sell	336,223 -263,777	-44%	-$6.21M	0.08%	126
2021 Q3	$19.3M	Hold	600,000	–	–	0.25%	97
2021 Q2	$20.3M	Hold	600,000	–	–	0.27%	93
2021 Q1	$22.5M	Hold	600,000	–	–	0.33%	88
2020 Q4	$19.9M	Buy	600,000 +150,000	+33%	+$6.08M	0.31%	91
2020 Q3	$16.5M	Hold	450,000	–	–	0.32%	85
2020 Q2	$14.8M	Hold	450,000	–	–	0.32%	80
2020 Q1	$11.6M	Hold	450,000	–	–	0.38%	78
2019 Q4	$14M	Buy	+450,000	New	+$11.3M	0.39%	69

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Eventide Asset Management's PHAT Position: Q3 2022 in Review

Eventide Asset Management sold out of Phathom Pharmaceuticals (PHAT) in Q3 2022, closing a stake of 336,223 shares — an estimated $2.84M sold.

Eventide Asset Management first reported a position in PHAT in Q4 2019 and held it in 11 quarters. The position peaked at $22.5M in Q1 2021. 94 funds tracked by Wall St. Rank hold PHAT as of Q3 2022.

Eventide Asset Management reported no remaining Phathom Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Eventide Asset Management sold 336,223 Phathom Pharmaceuticals shares in Q3 2022, an estimated $2.84M.
Eventide Asset Management first reported a position in Phathom Pharmaceuticals in Q4 2019 and held it in 11 quarters.
Eventide Asset Management's Phathom Pharmaceuticals position peaked at $22.5M in Q1 2021.
94 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q3 2022.

Based on Eventide Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.